SEC to review Serum Institute qHPV vaccine trial data today

The application for market authorization of the qHPV vaccine was submitted to the DCGI on June 8 by Prakash Kumar Singh (director of government and regulatory affairs).

The vaccine is expected to be launched in the market before the end of 2022, sources told ANI. The qHPV will be India’s first indigenously curated vaccine against cervical cancer.

To ensure its early availability in the country, the Pune-based Serum Institute of India has applied for market authorization after completing the phase 2/3 clinical trial with the support of the Department of Biotechnology.

Read also: SII chief Dr Cyrus S Poonawalla conferred Dean’s Medal by Johns Hopkins Bloomberg School of Public Health

Cervical cancer in India ranks as the second-most frequent cancer among women between 15 and 44 years of age.  Cervical cancer develops in a woman’s cervix (the entrance to the uterus from the vagina). Almost all cervical cancer cases (99%) are linked to infection with high-risk human papillomaviruses (HPV), an extremely common virus transmitted through sexual contact.  Although most infections with HPV resolve spontaneously and cause no symptoms, persistent infection can cause cervical cancer in women.